Open AccessUnderstanding and leveraging cell metabolism to enhance mesenchymal stem cell transplantation survival in tissue engineering and regenerative medicine applications
Author(s) -
SalazarNoratto Giuliana E.,
Luo Guotian,
Denoeud Cyprien,
Padrona Mathilde,
Moya Adrien,
Bensidhoum Morad,
Bizios Rena,
Potier Esther,
LogeartAvramoglou Delphine,
Petite Hervé
Publication year - 2020
Publication title -
stem cells
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.159
H-Index - 229
eISSN - 1549-4918
pISSN - 1066-5099
DOI - 10.1002/stem.3079
Subject(s) - mesenchymal stem cell , regenerative medicine , transplantation , biology , stem cell , cell metabolism , cell , cell therapy , bioinformatics , microbiology and biotechnology , medicine , genetics
In tissue engineering and regenerative medicine, stem cell—specifically, mesenchymal stromal/stem cells (MSCs)—therapies have fallen short of their initial promise and hype. The observed marginal, to no benefit, success in several applications has been attributed primarily to poor cell survival and engraftment at transplantation sites. MSCs have a metabolism that is flexible enough to enable them to fulfill their various cellular functions and remarkably sensitive to different cellular and environmental cues. At the transplantation sites, MSCs experience hostile environments devoid or, at the very least, severely depleted of oxygen and nutrients. The impact of this particular setting on MSC metabolism ultimately affects their survival and function. In order to develop the next generation of cell‐delivery materials and methods, scientists must have a better understanding of the metabolic switches MSCs experience upon transplantation. By designing treatment strategies with cell metabolism in mind, scientists may improve survival and the overall therapeutic potential of MSCs. Here, we provide a comprehensive review of plausible metabolic switches in response to implantation and of the various strategies currently used to leverage MSC metabolism to improve stem cell‐based therapeutics.